companiesCompany
Bulsara Bioworks
Bulsara Bioworks is a 2025 start-up focused on precise p53-pathway activation for solid tumours.
Bulsara Bioworks (founded 2025, San Francisco; backed by Even One Ventures) describes a focused drug-development model around p53 pathway biology and precision p53 activation in solid tumours. Preclinical; exhibited at BIO 2026.
Pages like this
not linked directly; found by shared links- IdeaDegrade the damaged p53 protein rather than trying to repair it
Shares p53 / RB / cell-cycle checkpoint, TP53.
- IdeaExtend p53 reactivation beyond the Y220C mutation
Shares p53 / RB / cell-cycle checkpoint, TP53.
- ProductEprenetapopt
Shares p53 / RB / cell-cycle checkpoint, TP53.
- CompanyFinalDose
Shares TP53 and the tag early-stage.
- TermWhole-genome doubling (WGD)
Shares p53 / RB / cell-cycle checkpoint, TP53.
- IdeaMilestone prizes for first-in-class mechanisms reaching human proof of concept
Shares p53 / RB / cell-cycle checkpoint, TP53.
- TargetMDM2
Shares p53 / RB / cell-cycle checkpoint, TP53.
- TermHallmark: evading growth suppressors
Shares p53 / RB / cell-cycle checkpoint, TP53.